Application of preoperative artificial neural network based on blood biomarkers and clinicopathological parameters for predicting long-term survival of patients with gastric cancer

Table 2 Univariate logistics regression analysis of risk factors for the 3-year survival

Variable	Training set
	OR	95CI		P value
Age (yr)
< 57	REF
57-74	0.38	0.25	0.58	< 0.001
> 74	0.63	0.42	0.93	0.020
Sex
Male	REF
Female	0.96	0.72	1.29	0.782
BMI
< 18.5	REF
18.5-23.5	3.04	1.90	4.85	< 0.001
> 23.5	1.28 357	0.95	1.73	0.111
CEA
< 2.8	REF
2.8-4.8	0.33	0.24	0.45	< 0.001
> 4.8	0.46	0.31	0.67	< 0.001
CA199
< 15.0	REF
15.0-39.2	0.20	0.14	0.29	< 0.001
> 39.2	0.33	0.22	0.50	< 0.001
AFP
< 2	REF			< 0.001
2-5.29	0.78	0.51	1.18	0.240
> 5.3	0.50	0.33	0.74	0.001
NLR
< 1.91	REF
1.91-3.87	0.32	0.22	0.48	< 0.001
> 3.87	0.48	0.33	0.69	< 0.001
PLR
< 89.5	REF
89.5-162.3	0.26	0.16	0.42	< 0.001
> 162.3	0.59	0.45	0.78	< 0.001
AGR
< 6.59	REF
6.59-7.81	2.11	1.50	2.98	< 0.001
> 7.81	1.58	1.13	2.20	0.007
PNI
< 371	REF
371-430	3.98	2.62	6.06	< 0.001
> 430	1.94	1.29	2.92	0.002
ASA
I	REF
II	0.44	0.24	0.79	0.006
III-IV	0.53	0.29	0.97	0.041
Comorbidity
No	REF
Yes	0.99	0.74	1.31	0.933
Primary site
Lower	REF
Middle	0.30	0.20	0.45	< 0.001
Upper	0.54	0.35	0.83	0.001
Overlapping lesion of the stomach	0.47	0.31	0.73	< 0.001
Tumor size (mm)
< 30	REF
30-60	0.08	0.06	0.13	< 0.001
> 60	0.43	0.31	0.60	< 0.001
cT
T1	REF
T2	0.05	0.02	0.13	< 0.001
T3	0.18	0.11	0.32	< 0.001
T4	0.24	0.17	0.34	< 0.001
cN
N0	REF
N1	0.18	0.12	0.27	< 0.001
N2	0.28	0.18	0.43	< 0.001
N3	0.67	0.44	1.007	0.054

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 19-9; AFP: Alpha fetoprotein; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; AGR: Albumin-globulin ratio; PNI: Prognostic nutrition index; ASA: American society of anesthesiologists; cT: Clinical T stage; cN: Clinical N stage; OR: Odds ratio; CI: Confidence interval.